Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

May 17, 2018

|

NEW YORK (GenomeWeb) – Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.

The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Model of Discovery

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

Subcommittee Calls for More Funding

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

Limit of Relevance

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

This Week in PLOS

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.

Menu